Compound loss of muscleblind‐like function in myotonic dystrophy
Abstract Myotonic dystrophy (DM) is a multi‐systemic disease that impacts cardiac and skeletal muscle as well as the central nervous system (CNS). DM is unusual because it is an RNA‐mediated disorder due to the expression of toxic microsatellite expansion RNAs that alter the activities of RNA proces...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2013-10-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/emmm.201303275 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203683444228096 |
|---|---|
| author | Kuang‐Yung Lee Moyi Li Mini Manchanda Ranjan Batra Konstantinos Charizanis Apoorva Mohan Sonisha A. Warren Christopher M. Chamberlain Dustin Finn Hannah Hong Hassan Ashraf Hideko Kasahara Laura P. W. Ranum Maurice S. Swanson |
| author_facet | Kuang‐Yung Lee Moyi Li Mini Manchanda Ranjan Batra Konstantinos Charizanis Apoorva Mohan Sonisha A. Warren Christopher M. Chamberlain Dustin Finn Hannah Hong Hassan Ashraf Hideko Kasahara Laura P. W. Ranum Maurice S. Swanson |
| author_sort | Kuang‐Yung Lee |
| collection | DOAJ |
| description | Abstract Myotonic dystrophy (DM) is a multi‐systemic disease that impacts cardiac and skeletal muscle as well as the central nervous system (CNS). DM is unusual because it is an RNA‐mediated disorder due to the expression of toxic microsatellite expansion RNAs that alter the activities of RNA processing factors, including the muscleblind‐like (MBNL) proteins. While these mutant RNAs inhibit MBNL1 splicing activity in heart and skeletal muscles, Mbnl1 knockout mice fail to recapitulate the full‐range of DM symptoms in these tissues. Here, we generate mouse Mbnl compound knockouts to test the hypothesis that Mbnl2 functionally compensates for Mbnl1 loss. Although Mbnl1−/−; Mbnl2−/− double knockouts (DKOs) are embryonic lethal, Mbnl1−/−; Mbnl2+/− mice are viable but develop cardinal features of DM muscle disease including reduced lifespan, heart conduction block, severe myotonia and progressive skeletal muscle weakness. Mbnl2 protein levels are elevated in Mbnl1−/− knockouts where Mbnl2 targets Mbnl1‐regulated exons. These findings support the hypothesis that compound loss of MBNL function is a critical event in DM pathogenesis and provide novel mouse models to investigate additional pathways disrupted in this RNA‐mediated disease. |
| format | Article |
| id | doaj-art-e6ecfc7eb11f40d5b72afc0761cf559b |
| institution | OA Journals |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2013-10-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-e6ecfc7eb11f40d5b72afc0761cf559b2025-08-20T02:11:26ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842013-10-015121887190010.1002/emmm.201303275Compound loss of muscleblind‐like function in myotonic dystrophyKuang‐Yung Lee0Moyi Li1Mini Manchanda2Ranjan Batra3Konstantinos Charizanis4Apoorva Mohan5Sonisha A. Warren6Christopher M. Chamberlain7Dustin Finn8Hannah Hong9Hassan Ashraf10Hideko Kasahara11Laura P. W. Ranum12Maurice S. Swanson13Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Physiology and Functional Genomics, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Physiology and Functional Genomics, University of Florida, College of MedicineDepartment of Physiology and Functional Genomics, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineDepartment of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of MedicineAbstract Myotonic dystrophy (DM) is a multi‐systemic disease that impacts cardiac and skeletal muscle as well as the central nervous system (CNS). DM is unusual because it is an RNA‐mediated disorder due to the expression of toxic microsatellite expansion RNAs that alter the activities of RNA processing factors, including the muscleblind‐like (MBNL) proteins. While these mutant RNAs inhibit MBNL1 splicing activity in heart and skeletal muscles, Mbnl1 knockout mice fail to recapitulate the full‐range of DM symptoms in these tissues. Here, we generate mouse Mbnl compound knockouts to test the hypothesis that Mbnl2 functionally compensates for Mbnl1 loss. Although Mbnl1−/−; Mbnl2−/− double knockouts (DKOs) are embryonic lethal, Mbnl1−/−; Mbnl2+/− mice are viable but develop cardinal features of DM muscle disease including reduced lifespan, heart conduction block, severe myotonia and progressive skeletal muscle weakness. Mbnl2 protein levels are elevated in Mbnl1−/− knockouts where Mbnl2 targets Mbnl1‐regulated exons. These findings support the hypothesis that compound loss of MBNL function is a critical event in DM pathogenesis and provide novel mouse models to investigate additional pathways disrupted in this RNA‐mediated disease.https://doi.org/10.1002/emmm.201303275Mbnl1Mbnl2muscleblind‐likemyotonic dystrophyRNA‐mediated disease |
| spellingShingle | Kuang‐Yung Lee Moyi Li Mini Manchanda Ranjan Batra Konstantinos Charizanis Apoorva Mohan Sonisha A. Warren Christopher M. Chamberlain Dustin Finn Hannah Hong Hassan Ashraf Hideko Kasahara Laura P. W. Ranum Maurice S. Swanson Compound loss of muscleblind‐like function in myotonic dystrophy EMBO Molecular Medicine Mbnl1 Mbnl2 muscleblind‐like myotonic dystrophy RNA‐mediated disease |
| title | Compound loss of muscleblind‐like function in myotonic dystrophy |
| title_full | Compound loss of muscleblind‐like function in myotonic dystrophy |
| title_fullStr | Compound loss of muscleblind‐like function in myotonic dystrophy |
| title_full_unstemmed | Compound loss of muscleblind‐like function in myotonic dystrophy |
| title_short | Compound loss of muscleblind‐like function in myotonic dystrophy |
| title_sort | compound loss of muscleblind like function in myotonic dystrophy |
| topic | Mbnl1 Mbnl2 muscleblind‐like myotonic dystrophy RNA‐mediated disease |
| url | https://doi.org/10.1002/emmm.201303275 |
| work_keys_str_mv | AT kuangyunglee compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT moyili compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT minimanchanda compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT ranjanbatra compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT konstantinoscharizanis compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT apoorvamohan compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT sonishaawarren compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT christophermchamberlain compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT dustinfinn compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT hannahhong compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT hassanashraf compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT hidekokasahara compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT laurapwranum compoundlossofmuscleblindlikefunctioninmyotonicdystrophy AT mauricesswanson compoundlossofmuscleblindlikefunctioninmyotonicdystrophy |